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Herpes simplex virus type 1 (HSV-1) infection has a prevalence of 70% in the human population. Treatment is based on acyclovir,
valacyclovir, and foscarnet, three drugs that share the same mechanism of action and of which resistant strains have been isolated
from patients. In this aspect, innovative drug therapies are required. Natural products oﬀer unlimited opportunities for the
discovery of antiviral compounds. In this study, 28 extracts corresponding to 24 plant species and 4 alga species were assayed
in vitro to detect antiviral activity against HSV-1. Six of the methanolic extracts inactivated viral particles by direct interaction and
14 presented antiviral activity when incubated with cells already infected. Most interesting antiviral activity values obtained are
those of Limonium brasiliense, Psidium guajava, and Phyllanthus niruri, which inhibit HSV-1 replication in vitro with 50% eﬀective
concentration (EC50) values of 185, 118, and 60µg/mL, respectively. For these extracts toxicity values were calculated and therefore
selectivity indexes (SI) obtained. Further characterization of the bioactive components of antiviral plants will pave the way for the
discovery of new compounds against HSV-1.
1.Introduction
Herpes simplex virus type 1 (HSV-1), a member of the Her-
pesviridae family, is a double-stranded DNA virus, extremely
widespread in the human population [1, 2] with prevalence
ranging from 60 to more than 95% [3]. It is responsible for
abroadrangeofdisorders,includinggingivostomatitis,kera-
toconjunctivitis,genitaldisease,andencephalitis[4],causing
more severe illnesses in newborns and immunocompro-
mised patients [5].
Several drugs, acyclovir, vidarabine, phosphonoformic
acid, and other compounds including interferon, are used
to treat HSV-associated diseases [6]. However, an increasing
amount of drug-resistant strains have been isolated in the
last few years, thus limiting the eﬃcacy of these drugs [7]
and enhancing the need for drugs that innovate in the viral
targets or/and the mechanisms of action.
It is estimated that 40% of modern drugs derived from
natural sources [8]. Ethnopharmacological knowledge and
texts of traditional herbal medicine usage have been an
important source of information and have shown to be very
eﬃcient in the identiﬁcation of bioactive compounds, even
whencomparedtothestandardhighvolumerandomscreen-
ing method [9]. South American ﬂora has been explored for
bioactive compounds with remarkable results, including the
antioxidant properties of Achyrocline satureioides commonly
known as “Marcela” [10], capability of Phyllanthus niruri of
dissolving kidney and gall stones [11], and the Echinacea
purpurea anti-inﬂuenza virus properties [12].
Standardized cultivation of viruses is a powerful ap-
proachforinvitrodrugtestingthatincludesthepossibilityof
comparison with reference drugs. The aim of this study was
to challenge extracts of a set of South American plants to in-
hibit HSV-1 replication in a mammalian cell culture model.2 The Scientiﬁc World Journal
For this, 28 ethanolic extracts corresponding to 24 plant and
4 alga species were prepared and assayed in vitro to detect
selectiveantiviralactivity.AllspeciesarefoundinUruguayan
soilandreportsdescribingusageintraditionalmedicineexist
for all of them. Moreover, some of the plants are speciﬁcally
recommended to treat genital, throat, eyes, and mouth sores
and itching.
2.MaterialsandMethods
2.1. Plant and Algae Material. The collection of all plant
and algae species was made in their natural environment in
southern Uruguay, except for Phyllanthus niruri that was
bought from Botica del Se˜ nor SRL (Lot N◦3-Int. 1/07). The
identiﬁcation of all materials was performed by Lic. Alonso
Paz and M. J. Bassagoda from the Department of Pharma-
ceutics Botanic of Facultad de Qu´ ımica, Universidad de la
Rep´ ublica. Voucher specimens have been deposited at the
herbarium of Facultad de Qu´ ımica, Universidad de la Re-
p´ ublica.
2.2. Preparation of Extracts. To prepare all ethanolic extracts
the plant material was dried and macerated for 48 hours in
EtOH:H2O (70:30v/v). The algae material was air-dried
and processed in the same way as plants except for Gratelou-
pia ﬁlicina, where CHCL3 :MeOH(50:50v/v)wasusedfor
maceration. The liquid fractions were freeze-dried and solu-
bilized in DMSO to prepare stock and work solutions.
2.3. Cells, Virus, and Acyclovir. Vero cells (African green
monkey kidney, ATCC number CCL-81) were cultured in D-
MEM GlutaMAX-1 (Gibco Invitrogen) supplemented with
10% fetal bovine serum (FBS) (Gibco Invitrogen), 100µg/
mL Streptomycin, and 1000U/mL penicillin and grown at
37◦Ci na5 %C O 2 humidiﬁed atmosphere. The cell line used
in this work was Mycoplasma sp. free. HSV-1 strain F was
provided by Dra. Luc´ ıa Cavallaro from C´ atedra de Virolog´ ıa,
Facultad de Farmacia y Bioqu´ ımica, Universidad de Buenos
Aires, Argentina. Acyclovir was purchased from Laboratorio
Libra(Virulax250)andpreparedto1mg/mLinsterilewater.
2.4. Determination of MNCC and CC50. To evaluate the
eﬀect of the extracts on Vero cells viability, dilutions ranging
from 1000 to 16µg/mL were added on 85–95% conﬂuent
monolayers in 96-well culture plates. After 72 hours of incu-
bation, the maximum noncytotoxic concentration (MNCC)
for all extracts was determined by microscopic observation
and CC50 (extract concentration that is toxic for half of the
cells) was determined by the crystal violet uptake method.
Brieﬂy, cell monolayers were ﬁxed and stained with a crystal
violet 0.75% in 40% methanol solution and incubated for
15 minutes at 37◦C. Nonincorporated crystal violet dye was
removed. Retained dye in the cells was solubilized with an
acetic acid 20% solution, and the absorbance at 570nm was
measured in a microplate reader (Bio-Rad, Model 680).
2.5. Screening of Antiviral Activity by Cytopathic Eﬀect Reduc-
tion Assay. Primary antiviral screening test was conducted
by cytopathic eﬀect (CPE) reduction assay, which involves
the protection of viral-caused lysis of Vero cells by extracts.
Brieﬂy, in 96-well culture plate, 5 × 104UFP/mL of HSV-1
was inoculated on Vero cells. After 1 hour of adsorption at
37◦Ci na5 %C O 2 humidiﬁed atmosphere, cells were washed
withphosphatebuﬀersaline(PBS)and2-foldserialdilutions
of the correspondent extract beginning at the MNCC were
added. Cytotoxicity and cell controls were included. After
72 hours of incubation at 37◦Ci na5 %C O 2 humidiﬁed
atmosphere, cells were ﬁxed and stained as described in
Section 2.4.Theantiherpeticactivityoftheextractswaseval-
uated by direct observation of CPE reduction.
2.6. Determination of EC50 by Plaque Reduction Assay. To
determine the eﬀective concentration that inhibited 50%
of plaque forming units (PFUs) (EC50) a standard plaque
reductionassaywasconducted.Brieﬂy,Verocellsmonolayers
g r o w ni n4 8 - w e l lc u l t u r ep l a t e sw e r ei n f e c t e dw i t h1 0 0P F U
of HSV-1. After 1 hour of adsorption at 37◦Ci na5 %C O 2
humidiﬁed atmosphere the cells were rinsed with PBS.
Twofold serial dilutions of the correspondent extract (begin-
ning from the MNCC) in medium containing 2% FBS and
0.8% methylcellulose were added. Each concentration was
tested in duplicate. Infected cultures were incubated for 48h
at37◦Cina5%CO 2 humidiﬁedatmosphere.Cellswereﬁxed
and stained as described (see above). Plaques were counted
andviraltitleexpressedasPFU/well.Viral,cellular,andcyto-
toxic controls were performed in each assay. Acyclovir was
included as a positive inhibition control.
2.7. Virucidal Activity Assay. To evaluate the presence of
virucidalactivity,directinactivationofHSV-1bytheextracts
wastested.Toassayvirucidalactivity,a5 ×109 UFP/mLviral
inoculum was mixed with extracts at three serial concentra-
tions (MNCC, MNCC/2, and MNCC/4) and incubated at
room temperature for 1 hour. After that, viral inoculum was
dilutedinmediumsupplementedwith2%FBStoa500UFP/
mL concentration. Surviving infectious viral particles were
measured by standard plaque reduction assaywith respect to
the control in which virus was mixed with medium sup-
plemented with 2% FBS. Cell controls were included. Extract
wasconsideredpositivewhenitinactivated ≥90%oftheviral
particles with respect to a control.
2.8. Data Analysis. CC50 and EC50 for each extract were ob-
tained from dose-eﬀect curves (data not shown). The values
correspond to the average and standard deviation of three
independent assays with at least 5 concentrations within
the inhibitory range. The selectivity index (IS) is deﬁned as
CC50/EC50.
3. Results
Among the 27 extracts tested only 16 plant species presented
anti-HSV-1 activity. MNCC, EC50, and virucidal activity val-
u e so b t a i n e df o re a c he x t r a c ta r es h o w e di nTable 1. No anti-
viral activity was detected in the algae extracts. Extracts with
anti-HSV-1 activity were also tested for virucidal activity.The Scientiﬁc World Journal 3
Table 1: Antiviral and virucidal activity of each plant and algae species.
Species MNCC
a (µg/mL) Antiviral activity EC50
b (µg/mL) Virucidal activity (%)
Plants
Achyrocline satureioides 2500 + 380 <90
Apium leptophyllum 5000 − ND ND
Bauhinia candicans 1250 + 1060 85
Chenopodium ambrosioides 2500 + 920 90
Conyza bonariensis 630 − ND ND
Eryngium pandanifolium 1250 − ND ND
Heimia salicifolia 1250 − ND ND
Ibicella lutea 1250 − ND ND
Jaborosa runcinnata 1250 − ND ND
Lentinus edulis 5000 − ND ND
Limonium brasiliense 500 + 185 99
Margyricarpus pinnatus 1250 + 320 95
Phyllanthus niruri 120 + 60 39
Polygonum punctatum 1250 + 1230 <90
Psidium incanum 250 + 118 20
Psidium luridum 310 + 1500 88
Schinus molle 630 + 50 <90
Salvia guaranitica 250 − ND ND
Sesbania punicea 1250 + 1100 <90
Smilax gracilis 2500 + 470 90
Sommerfeltia spinulosa 1250 − ND ND
Tillandsia aeranthos 2500 + 530 93
Tillandsia usneoides 1250 + 470 91
Xanthium spinosum 1250 − ND ND
Algae
Corallina oﬃcinalis 630 − ND ND
Chondria atropurpurea 1250 − ND ND
Grateloupia ﬁlicina 2500 − ND ND
Hypnea musciformis 630 − ND ND
Acyclovir 120 + 45 99
aMaximum noncytotoxic concentration.
bEﬀective concentration 50%.
N/D: not determined.
+ Positive antiviral activity in the screening assay.
In this experiment 6 of them showed virucidal values ≥90%
of PFU reduction.
WithrespecttoantiviralactivityandEC50 determination,
Psidium guajava, Phyllanthus niruri, and Limonium brasi-
lienseextractshadthehighestvalues:118,60,and185µg/mL,
respectively. In addition, for the three extracts CC50 values
weredeterminedinmammaliancellsandSIwascalculatedin
each case. P. niruri presented the highest SI (42.37), followed
byP. guajava (14.89).L.brasilienseshowedanSIof4.58.CC50
and SI values are shown in Table 2.
4. Discussion and Conclusions
The limited eﬃcacy of the current treatment of HSV-1 in-
fection enhances the need for novel therapies that include
drugs with innovative viral targets and/or mechanisms of
action. Since approximately 40% of modern drugs derived
from natural sources and Ethnopharmacological knowledge
Table 2: CC50 and SI calculated for each anti-HSV-1 extract.
Plant species CC50
a (µg/mL) SIb
Psidium incanum 1756 14.89
Phyllanthus niruri 2542 42.37
Limonium brasiliense 848 4.58
Acyclovir 3190 70.9
aCytotoxic concentration 50%.
bSelectivity index. Ratio CC50/EC50.
has been an important source of information for the identiﬁ-
cation of bioactive compounds, we conducted this investiga-
tion with the aim to identify natural sources of compounds
thatcouldbepotentiallyincludedinaformulationtobeused
in therapy against HSV-1.
This work shows that ethanolic extracts of 16 plant spe-
cies exhibit in vitro antiherpetic activity. The fact that 60%4 The Scientiﬁc World Journal
of all the plants assayed resulted positive demonstrates once
again that traditional knowledge of medicinal plant usage
is an eﬃcient way of identifying biological and particularly
antimicrobial activity. Half of the 16 positive plants showed
EC50 values below 500µg/mL, about ten times greater than
that of acyclovir, which is a puriﬁed compound. Among
these, P. niruri, Psidium incanum, and L. brasiliense showed
the highest anti-HSV-1 activity as was determined in plaque
reduction assay.
It is important to emphasize that the value obtained for
P. niruri (EC50 = 60µg/mL) clearly correlates with its tradi-
tional use [13, 14]. In fact, this species is used to treat skin
ulcers,sores,swelling,anditchinessoftheskin[15]andother
several illnesses including kidney and gall stones [9], jaun-
dice, gonorrhea, and diabetes [16]. It also has been tested for
antiviral activity against inﬂuenza [17], hepatitis B [18–20],
and human immunodeﬁciency virus (HIV) [16]. Our results
are in accordance with previous reports of antiherpetic
activity of several species of the Phyllanthus genera [21–24].
With respect to P. guajava and L. brasiliense, there is no data
abouttheirantiherpeticactivity.Infact,thisistheﬁrstreport
demonstrating the inhibitory eﬀect of HSV-1 replication in
vitroof these plants. Remarkably, the three plant species have
been widely used in traditional medicine by South American
ancient populations for the treatment of several illnesses
[13, 25].
Since an antiviral compound should combine the highest
eﬀectiveness with the lowest cytotoxicity, it was important
to evaluate the SI in order to determine the potential appli-
cation of extract-derived compounds as antiviral agents. P.
niruri has the highest SI resulting of a low CC50 value com-
bined with a high aﬀectivity.
L. brasiliense has an encouraging value of antiviral eﬀec-
tivity (EC50 = 185µg/mL), but the ethanolic extract of this
plant is also highly toxic resulting in an SI of 4.58. Since
ethanolic extracts are complex and heterogeneous and com-
pounds of diﬀerent chemical origin are present, it might be
possible to separate toxic molecules from those responsible
of the antiviral activity. For these, further studies with puri-
ﬁcation fractions of the extract should be carried out.
On the other hand, it was important to diﬀerentiate di-
rect viral particle inactivation from antiviral activity. In fact,
virucidal activity might eclipse antiviral activity if tests of
directinactivationofviralparticlesarenotperformed.Inour
study, 6 plant extracts presented a positive activity (plaque
reductionhigher ≥90%).Forthisextractsonemightassume
that part of their activity relies on direct inactivation of the
viral particles after virus adsorption and that this might also
be occurring in the antiviral assay. However, this is not the
case for extracts that combine low or no virucidal activity
with positive antiviral activity (i.e., P. niruri, P. incanum,
Apium leptophyllum, andConyzabonariensis).Fortheseanti-
HSV-1 species another mechanism of action should exist
since they act in postabsorption steps of the viral cycle.
The results presented here justify further investigation
of the extracts by bioguided fractionation procedures that
hopefully will allow to identify active molecule(s) involved
in anti-HSV-1 activity. If puriﬁed compounds with at least
the antiviral values showed here are identiﬁed, this will turn
theminto candidates for invivo trialsandfutureantiherpetic
formulations.
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